Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  etoposide phosphate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 86 for your search:
Start Over
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-00055-18, NCT00415103
Retrospect Stage IND EXEMPT Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Phase: Phase IV
Type: Biomarker/Laboratory analysis
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: FWA00015357, NPI - 1831468511, NPI - 1023387701, IRB00009424, IORG0007849, NCT01064466
Bevacizumab in Extensive Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to under 30
Sponsor: NCI, Other
Protocol IDs: AALL0433, NCI-2009-00306, COG-AALL0433, CDR0000495359, U10CA098543, NCT00381680
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000531141, CRUK-LUNGSTAR, EU-20649, ISRCTN56306957, EUDRACT-2005-005821-71, UCL-BRD/05/129, MREC-06-MRE10-28, CTA-20363-0215-001, CTAAC-C1312-A5335, CTAAC-C1312-A12462, NCT00433498
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 21 and under at the time of definitive surgery
Sponsor: NCI, Other
Protocol IDs: ACNS0333, NCI-2009-00337, COG-ACNS0333, U10CA098543, NCT00653068
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: D0750018, NCT00660504
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Phase: Phase III
Type: Supportive care, Treatment
Status: Temporarily closed
Age: Under 30 at initial diagnosis
Sponsor: NCI, Other
Protocol IDs: AREN0534, NCI-2011-01953, CDR0000649716, U10CA180886, U10CA098543, COG-AREN0534, NCT00945009
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO21800205, NCT00315705
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 08-005, NCT00702962
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 07053, P30CA033572, CHNMC-07053, CA180 121, CDR0000617760, NCT00788125
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060534, NCT00791154
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 10-0910 / 201106039, NCT00906945
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CWRU4196, P30CA043703, BMS-CRWU-4196, NCI-G00-1854, NCT00006260
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 30 and under at original diagnosis
Sponsor: NCI, Other
Protocol IDs: ANBL00P1, COG-ANBL00P1, CDR0000068681, NCT00017368
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000276590, U10CA021115, E5501, ECOG-5501, NCT00057837
Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 59
Sponsor: Other
Protocol IDs: LL03, NCT00195871
Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: Other
Protocol IDs: CNS 0294, NCT00179920
Start Over